A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

To join this study, people need to be at least 18 years old and have a confirmed diagnosis of lower-risk myelodysplastic syndromes (LR-MDS). Your doctor will have classified your condition as 'lower-risk' and checked that you have less than 5% abnormal cells in your bone marrow.

Another important part of joining is your recent history with blood transfusions. You could be eligible if you haven't had many transfusions recently, or none at all. Specifically, if you've had fewer than 3 blood transfusions in the last 16 weeks and none in the last 8 weeks, or if you've had between 3 and 7 transfusions in the last 16 weeks but fewer than 4 in the last 8 weeks, you might be able to take part. Your blood count (haemoglobin) also needs to be below a certain level.

Your general health and ability to do daily activities, as assessed by your doctor, are also taken into account. If you are taking medication to remove excess iron from your body, it needs to have been at a steady dose for at least 8 weeks. For safety, women who could become pregnant and men with partners who could become pregnant will need to use effective contraception throughout the study.

The detailed involvement in this study isn't fully described here, but generally, taking part in a clinical trial like this would involve regular visits to the clinic. During these visits, you would have medical check-ups, blood tests, and other assessments to monitor your health and how you're responding to the study medicine, tebapivat. You would take the study medicine as directed by the research team.

There would also be follow-up appointments after you stop taking the medicine to ensure your well-being. The total length of your participation, including the treatment and follow-up periods, is not specified in this brief summary but would be clearly explained by the study team if you decide to inquire further.